In light of current evidence, immune checkpoint inhibitors are considered a standard treatment for patients with CM, and BRAF/MEK inhibitors are recommended in patients with melanoma and BRAF V600E/K mutations [10,11,12]. Here, BRAF is linked to melanoma.